Patients with metastatic papillary renal cell carcinoma are likely to benefit from the durvalumab–savolitinib combination, show findings from the 1-year follow-up of the CALYPSO trial.
This independent news story was supported by an educational grant from Pfizer and Merck KGaA
Treatment with PD-1 inhibitors offers better overall survival, with comparable tolerability, than does treatment with PD-L1 inhibitors for patients with solid tumors such as non-small-cell lung cancer, suggests a systematic review and meta-analysis.
Tumors from obese patients with clear cell renal cell carcinoma have higher angiogenesis scores than those from normal-weight patients, as well as differences in the tumor microenvironment, US researchers report.
Sarcopenia in cancer patients taking nivolumab is associated with an increased risk for immune-related acute limiting toxicity, independent of plasma nivolumab concentrations, study results suggest.
A meaningful proportion of patients with advanced renal cell carcinoma with variant histology or sarcomatoid differentiation respond to the immunotherapy combination of atezolizumab and bevacizumab without experiencing severe toxicity, phase II study data show.
Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.